Pfizer’s sickle cell disease candidate fails Phase III trial
Inclacumab was generally well tolerated in THRIVE-131
Inclacumab was generally well tolerated in THRIVE-131
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Rivaroxaban is used to treat venous thromboembolism
The agreement complements other PPAs for Sandoz production sites globally
Subscribe To Our Newsletter & Stay Updated